October saw subdued growth in the Indian pharmaceutical market (IPM), with growth remaining in the low single digits, mainly ...

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1078 in its ...

Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief ...

The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order ...

In July, a single-judge bench of the Delhi High Court restrained Zydus Lifesciences from selling its breast cancer drug in ...

IST, the barometer index, the S&P BSE Sensex declined 211.60 points or 0.29% to 77,366.38. The Nifty 50 index lost 63.50 points or 0.27% to 23,469.20.

Zydus had approached the Supreme Court challenging the Delhi High Court's order, which prevented the company from producing ...

Upholding the patent rights of Swiss pharmaceutical giant F-Hoffmann-La Roche AG, the Delhi High Court has once again ...

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adultsCosibelimab PDUFA goal date of December 28 for ...

The Delhi High Court recently restored a single-judge order restraining Indian Pharma company Zydus Lifesciences ...

Zydus Lifesciences Q2 Results Live : Zydus Lifesciences declared their Q2 results on 12 Nov, 2024, reporting a notable ...